Determination of 21-hydroxydeflazacort in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. Application to bioequivalence study

Journal of Mass Spectrometry

Volumn 35, Issue 3, 2000, Pages 440-445

  Ifa, Demian R ^a,d   Moraes, Maria E ^b   Moraes, Manuel O ^b   Santagada, Vincenzo ^c   Caliendo, Giuseppe ^c   De Nucci, Gilberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NONE   (Brazil)

Author keywords

Deflazacort; Liquid chromatography mass spectrometry; Metabolite; Quantification

Indexed keywords

DEFLAZACORT; DENACEN; DEXAMETHASONE ACETATE; ETHER; GLUCOCORTICOID; NITROGEN; SOLVENT; UNCLASSIFIED DRUG;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; EVAPORATION; EXTRACTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STANDARD;

ADOLESCENT; ADULT; ATMOSPHERIC PRESSURE; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MASS SPECTROMETRY; PREGNENEDIONES; QUALITY CONTROL; REFERENCE STANDARDS; THERAPEUTIC EQUIVALENCY;

EID: 0034098095     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9888(200003)35:3<440::AID-JMS955>3.0.CO;2-8     Document Type: Article

References (11)

1. Markham A, Bryson HM. Drugs 1995; 50: 317.
2. Rao N, Eller M, Arumugham T, Weir S. Eur. J. Drug Metab. Pharmacol. 1996; 21: 241.
3. Rao N, Bhargava VO, Reynolds DL, Eller MG, Weir SJ. Biopharm. Drug Dispos. 1996; 17: 753.
4. Mollmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H. Pharm. Res. 1995; 12: 1096.
5. Reynolds DL, Burmaster SD, Eichmeier LS. Biomed. Chromatogr. 1994; 8: 230.
6. Hirata H, Kasama T, Sawai Y, Fike RR. J. Chromatogr. B 1994; 658: 55.
7. Huang EC, Wachs T, Conboy JJ, Henion JD. Anal. Chem. 1990; 62: 713.
8. Marzo A. J. Pharm. Pharmacol. 1997; 49: 1259.
9. Polettini A, Bouland GM, Montagna M. J. Chromatogr B 1998; 713: 399.
10. Federal Register Part 320: Bioavailability and Bioequivalence Requirements. Food and Drug Administration: Washington, DC, 1985; 154.
11. Food and Drug Administration. Pharmacopeial Forum 1993; 19: 6501.